Quality of the treatment of metabolic syndrome;Qualität der therapie des metabolischen syndroms

Diabetes, Stoffwechsel und Herz

Volumn 15, Issue 1, 2006, Pages 9-18

  Ott, Petra ^a   Benke, I ^a   Kohler C ^a   Hanefeld, M ^a  

^a NONE

Author keywords

Hypercholesterolemia; Metabolic syndrome; Quality of treatment; Type 2 diabetes

Indexed keywords

EID: 77955240622     PISSN: 18617603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 Diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
2. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM: Cause-specific mortality in a population with Diabetes - south tees Diabetes mortality study. Diabetes Care 2002; 25: 43-48
3. Tuomilehto J, Rastenyte D, Jousilahti P, Sarti C, Vartiainen E: Diabetes mellitus as a risk factor for death from heart stroke. Prospective study of the middle-aged Finnish population. Stroke 1997; 27: 210-215
4. Austin AM, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardio-vascular risk factor. Am J Cardiol 1998; 81: 7-12
5. Austin AM: Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am J Epidemiol 1989; 129: 249-259
6. Bruno G, Merletti F, Biggeri A, Bargeroo G, Ferrero S, Runzo C, Cerai SP, Pagano G, Cavallo-Perin P: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 Diabetes - the Casale-Monferrato-Study. Diab Care 2004; 27: 2689-2694
7. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583
8. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, UKPDS Group: Association of glycaemia with macrovascular and microvascular complications of type 2 Diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
9. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holmann RR, UKPDS Group: Risk factors for coronary artery disease in non-Insulin dependent Diabetes mellitus: United Kingdom prospective Diabetes study (UKPDS 23). BMJ 1998; 316: 823
10. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 Diabetes. N Engl J Med 2003; 348: 383-393 (Pubitemid 36159355)
11. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999; 17: 151-183
12. Scherbaum WA, Landgraf R: Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft (DDG). Diab Stoffw 2002; 11 [Suppl 2]
13. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
14. Bierwirth RA, Kron P, Lippmann-Grob B, Funke K, Leinhos B, Grüneberg M, Huptas M, Weich KW, Münscher C, Potthoff F: Die TEMPOStudie: Kostenanalyse in der diabetologischen Schwerpunktpraxis und Definition diabetesspezifischer Risikoprofile. Diab Stoffw 2003; 12: 83-94
15. Charpentier G, Genes N, Vaur L, Amar J, Clerson P, Cambou JP, Gueret P: Control of Diabetes and cardiovascular risk factors in patients with type 2 Diabetes: a nationwide French survey. Diabetes Metab 2003; 29: 152-158
16. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G, Valentini M, Nicolucci A; QuED Study: Quality of care and outcomes in type 2 diabetic patients: a comparison between general practice and Diabetes clinics. Diabetes Care 2004; 27: 398-406
17. Goudswaard AN, Stolk RP, Zuithoff P, Rutten GE: Patient characteristics do not predict poor glycaemic control in type 2 Diabetes patients treated in primary care. Eur J Epidemiol 2004; 19: 541-545
18. Liebl A, Mata M, Eschwege E: Evaluation of risk factors for development of complications in Type II Diabetes in Europe. CODE-2 Advisory Board. Diabetologia 2002; 45;7: S23-28
19. Sämann A, Kaiser J, Seeliger S, Müller UA: Ergebnisse der Diabetes-Karte Thüringen 2003 - Ein Projekt zur kontinuierlichen Evaluierung und Optimierung der Behandlungsqualität in der primären Versorgung von Patienten mit Diabetes mellitus. Diab Stoffw 2004; 13: 287-294
20. Schulze J, Rothe U, Muller G, Kunath H.: Fachkommission Diabetes Sachsen: Verbesserung der Versorgung von Diabetikern durch das sächsische Betreuungsmodell. Dtsch Med Wochenschr 2003; 23: 1161-1166
21. Hauner H, Köster I, von Ferber L: Prävalenz des Diabetes mellitus in Deutschland 1998-2001 - Sekundärdatenanalyse einer Versichertenstichprobe der AOK Hessen/KV Hessen. Dtsch Med Wochenschr 2003; 128: 2632-2638
22. Ott P, Koehler C, Benke I, Hanefeld M and the DIG-study-physicians: Quality of control of components of the cardiometabolic syndrome and of hypercholesterolemia in type 2 diabetics in Germany - The DIG-study (Diabetes in Germany). In Vorbereitung
23. Bruno A, Grassi G, Dani F, Degiovanni M, Maghenzani G, Pagano G: Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital. Nutr Metab Cardiovasc Dis 2005; 15: 42-46
24. Krone W, Bohm M: Diabetes mellitus needs unrestricted evaluation of patient data to yield treatment progress. The DUTY Register. Bundesgesundheitsblatt Gesundheitsforschung und Gesundheitsschutz 2004; 47: 540-546
25. Liebl A, Spannheimer A, Reitberger U, Wagenpfeil S, Görtz A: Aktuelles Diabetes-Management für Patienten mit Typ-2-Diabetes in Deutschland - Ergebnisse der CODE-2-Studie. Diab Stoffw 2002; 11: 55-61
26. U.K. Prospective Diabetes Study (UKPDS) Group 8: Study design, progress and performance. Diabetologia 1997; 34: 877-890
27. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, Holle R: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39: 1540-1545
28. Hanefeld M, Koehler C, Benke I, Ott P: Prevalence of the Metabolic Syndrome and its association with vascular diseases in type 2 Diabetes: The Diabetes in Germany(DIG)Study. In Vorbereitung
29. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA: Evidence of suboptimal management of cardiovascular risk in patients with type 2 Diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004; 171:1189-1192
30. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, De Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-Enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616 (Pubitemid 29087980)
31. Heart Outcomes Prevention Evalution (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with Diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259
32. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, De Faire U, Fyrquist F, Julius ST, Kjeldsen SE, Kristiansson K, Lederballe- Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelmann J, Snapinn ST: Cardiovascular morbidity and mortality in patients with Diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010 (Pubitemid 34286537)
33. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 Diabetes. N Engl J Med 2001; 345: 870-878
34. Rosenson RS, Reasner CA: Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 Diabetes. Curr Opin Cardiol 2004; 19: 480-487
35. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium-channel blockade in older patients with Diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677-684
36. Janka HU, Dirschedl P: Systolic blood pressure as a predictor for cardiovascular disease in Diabetes. A 5-year longitudinal study. Hypertension 1985; 7: II90-II94
37. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menhard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762 (Pubitemid 28269185)
38. Goderis G, Boland B: Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments. Acta Clin Belg 2004; 59: 329-339
39. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil AW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696
40. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of Cholesterol-Lowering with Simvastatin in 5963 People with Diabetes: a Randomised Placebo-Controlled Trial. Lancet 2003; 361: 2005-2026
41. Liebl A, Spannheimer A, Reitberger U, Görtz A: Ergebnisse der CODE-2-Studie - Arzneimitteltherapie und Medikationskosten von Patienten mit Diabetes Typ 2 in Deutschland. Diab Stoffw 2003; 12: 145-151
42. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
43. Gohlke H, Landgraf R, Scherbaum WA, Schwandt P, Standl E, Tschöpe D: Gemeinsame Stellungnahme zur evidenzbasierten Expertenleitlinie "Diabetes und Herz" der Deutschen Diabetes Gesellschaft (DDG) sowie den "Empfehlungen zur umfassenden Risikoverringerung für Patienten mit koronarer Herzerkrankung, Gefäßerkrankungen und Diabetes" der Deutschen Gesellschaft für Kardiologie (DGK). Z Kardiol 2002; 91: 1064-1065
44. American Diabetes Association: Dyslipidemia Management in Adults with Diabetes. Diabetes care 2004; 27: 68-71
45. Coon P, Zulkowski K: Adherence to American Diabetes Association standards of care by rural health care providers. Diabetes Care 2002; 25: 2224-2229
46. Grant RW, Buse JB, Meigs JB: Quality of Diabetes care in U.S. academic medical centers: rates of medical regimen change. Diabetes Care 2005; 28: 337-442
47. Supina AL, Guirguis LM, Majumdar SR, Lewanczuk RZ, Lee TK, Toth EL, Johnson JA: Treatment gaps for hypertension management in rural Canadian patients with type 2 Diabetes mellitus. Clin Ther 2004; 26;4: 598-606
48. Putzer G, Roetzheim R, Ramirez AM, Sneed K, Brownlee HJ Jr, Campbell RJ: Compliance with recommendations for lipid management among patients with type 2 Diabetes in an academic family practice. J Am Board Fam Pract 2004; 17: 101-107